BIND Therapeutics
101 Binney Street
Cambridge
Massachusetts
02142
United States
Tel: 617-491-3400
Fax: 617-491-0351
Website: http://www.bindbio.com/
Email: info@bindbio.com
133 articles about BIND Therapeutics
-
BIND Biosciences, Inc. Initiates Phase 1 Clinical Study of BIND-014, a First-in-Class Targeted Nanoparticle Therapeutic for Cancer
1/7/2011
-
BIND Biosciences, Inc. Presents Preclinical Data for Novel Nanomedicine, BIND-014, at American Chemical Society Meeting
8/23/2010
-
BIND Biosciences, Inc. Secures $12.4 Million Financing
6/29/2010
-
BIND Biosciences, Inc. Appoints Ed Schnipper, M.D., as Chief Medical Officer
6/29/2010
-
BIND Biosciences, Inc. Closes $11M Series C Financing Round
1/14/2010
-
BIND Biosciences, Inc. Appoints Scott Minick as President and CEO
1/11/2010
-
BIND Biosciences, Inc. Co-Founder Selected as 2009 Mass High Tech All-Star
10/29/2009
-
BIND Biosciences, Inc. To Install First Siemens Simatic(R) PCS 7 Lab Process Control System in the U.S.
3/17/2009
-
Massachusetts Biotechnology Council, Inc. Release: 19 Biotech Companies Selected to Present at 10th Annual MassBio Investors Forum
12/2/2008
-
BIND Biosciences, Inc. Appoints Jim Wright, PhD as Chief Scientific Officer
12/19/2007
-
BIND Biosciences, Inc. Closes $16M Series B Financing Round
11/27/2007
-
BIND Biosciences, Inc. Receives $2M NIST ATP Award to Develop a High-Throughput Platform for Targeted Nanoparticle Engineering
10/11/2007
-
BIND Biosciences, Inc. Awarded BIND Biosciences, Inc. Phase I National Institutes of Health (NIH) Contract to Develop Therapeutic Targeted Nanoparticles for Prostate Cancer Therapy
10/8/2007